Clinical Trial Update: Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 two-arm trial evaluating a DNA vaccine encoding PAP in non-metastatic castration-resistant prostate cancer has completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DNA vaccine encoding Prostatic Acid Phosphatase (PAP)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2014-09-11